<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825447</url>
  </required_header>
  <id_info>
    <org_study_id>B4981002</org_study_id>
    <nct_id>NCT01825447</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users</brief_title>
  <official_title>A Randomized, Single-Dose, Placebo-Controlled, Double-Blind, 3-Way Crossover Study to Determine the Relative Abuse Potential of Intravenous Oxycodone Hydrochloride Alone or in Combination With Intravenous Naltrexone Hydrochloride in Opioid Experienced Non-Dependent Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lifetree Clinical Research Center, Salt Lake City, Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to simulate if oxycodone and naltrexone combination
      capsules (ALO-02) were to be tampered with by dissolving and then injecting intravenously for
      the purpose of getting high.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Liking: Peak Effect (Emax)</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <description>High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again: Peak Effect (Emax)</measure>
    <time_frame>12, 24 h post-dose</time_frame>
    <description>Take Drug Again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100-point bipolar VAS with score ranging from 0 mm to 100 (score of 0 =</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again: Mean Effect (Emean)</measure>
    <time_frame>12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking: Peak Effect (Emax)</measure>
    <time_frame>12, 24 h post-dose</time_frame>
    <description>Overall Drug Liking VAS assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100-point VAS is used to assess response based on a score ranging from 0 to 100 (0 =</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking: Mean Effect (Emean)</measure>
    <time_frame>12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1 h post-dose</time_frame>
    <description>Pupillometry assessments measured change in pupil size (miosis) as an indicator of opioid pharmacological properties. The same eye for each participant was used for all measurements during the study. Participants have the size of their pupil measured (in mm) using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Liking: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Oxycodone 5 Minutes Post-Dose (C5min)</measure>
    <time_frame>pre-dose, 5 min post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Oxymorphone 5 Minutes Post-Dose (C5min)</measure>
    <time_frame>pre-dose, 5 min post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Noroxycodone 5 Minutes Post-Dose (C5min)</measure>
    <time_frame>pre-dose, 5 min post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Naltrexone 5 Minutes Post-Dose (C5min)</measure>
    <time_frame>pre-dose, 5 min post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of 6-beta-naltrexol 5 Minutes Post-Dose (C5min)</measure>
    <time_frame>pre-dose, 5 min post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Oxycodone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Oxymorphone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Noroxycodone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Naltrexone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of 6-beta-naltrexol</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxycodone Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <description>AUC is a measure of the plasma concentration of the drug over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxymorphone Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Noroxycodone Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Naltrexone Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxycodone Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxymorphone Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Noroxycodone Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Naltrexone Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxycodone Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxymorphone Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Noroxycodone Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Naltrexone Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Oxycodone Concentration (AUClast)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Oxymorphone Concentration (AUClast)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Noroxycodone Concentration (AUClast)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Naltrexone Concentration (AUClast)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable 6-beta-naltrexol Concentration (AUClast)</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for Oxycodone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for Oxymorphone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for Noroxycodone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for Naltrexone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for 6-beta-naltrexol</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl) of Oxycodone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl) of Oxymorphone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl) of Noroxycodone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl) of Naltrexone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl) of 6-beta-naltrexol</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for Oxycodone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for Oxymorphone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for Noroxycodone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for Naltrexone</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for 6-beta-naltrexol</measure>
    <time_frame>pre-dose, 5 min, 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone + Naltrexone</intervention_name>
    <description>Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Non-dependent, recreational opioid users

          -  Must include at least one of these routes of administration: intranasal use on at
             least 3 occassions in the past year or intravenous use on at least 1 occasion in the
             past year before Screening (Visit 1).

        Exclusion Criteria:

          -  Diagnosis of substance and/or alcohol dependence

          -  Subject has participated in, is currently participating in, or seeking treatment for
             substance and/or alcohol related disorder

          -  History of sleep apnea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4981002&amp;StudyName=A%20Study%20to%20Characterize%20the%20Abuse%20Liability%20of%20Intravenous%20Oxycodone%20Alone%20or%20in%20Combination%20with%20Intravenous%20Naltrexone%20in%20Healthy%2C%20N</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abuse potential</keyword>
  <keyword>abuse liability</keyword>
  <keyword>drug liking</keyword>
  <keyword>oxycodone</keyword>
  <keyword>naltrexone</keyword>
  <keyword>intravenous</keyword>
  <keyword>pharmacodynamic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

